| 000 | 01158 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250515072649.0 | ||
| 264 | 0 | _c20070629 | |
| 008 | 200706s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMct071462 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRansohoff, Richard M | |
| 245 | 0 | 0 |
_aNatalizumab for multiple sclerosis. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cJun 2007 |
||
| 300 |
_a2622-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aCentral Nervous System _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntegrin alpha4 |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 | _aNatalizumab |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 356 _gno. 25 _gp. 2622-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMct071462 _zAvailable from publisher's website |
| 999 |
_c17119530 _d17119530 |
||